We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

Boss also lowered his FY gross margin to 58.8%, representing a 70-basis point decline year-over-year, attributed to headwinds ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

J.P. Morgan analyst Ranjan Sharma maintained a Buy rating on Grab (GRAB – Research Report) on January 21 and set a price target of $5.60. The ...

Jamie Dimon, chairman and CEO, noted in the release that in the asset and wealth management division client net inflows ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers ...

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...

J.P. Morgan analyst Mark Strouse maintained a Hold rating on Bloom Energy (BE – Research Report) yesterday and set a price target of $16.00.

Investing.com -- J.P. Morgan analysts have upgraded their rating for Aviva plc (LON: AV) to "overweight" from "neutral," ...